
Ichor TriGrid -Delivery System
Ichor® is dedicated to the clinical application and commercialization of electroporation-mediated nucleic acid delivery. Ichor’s proprietary TriGrid Delivery System uses electrical fields to significantly enhance nucleic acid delivery as compared to conventional injection.
Ichor’s TriGrid Delivery System is an investigational device designed to enhance the intracellular delivery of nucleic acid constructs in skeletal muscle. The system is comprised of three main components.
The Pulse Stimulator controls the administration sequences and generates the electroporation pulses.
The Integrated Applicator is a reusable handheld device that houses the single-use cartridge. It automatically deploys the electrodes and initiates administration of the biologic agent at the touch of a single button. Its automated design ensures a reproducible application procedure with minimal operator training.
The Application Cartridge is a sterile, single-use component that houses the nucleic acid construct to be administered and a TriGrid electrode array for the electroporation procedure.
Ichor’s next-generation TriGrid Delivery System includes device refinements to support commercial deployment:
- Compatible with pre-filled syringe format
- Improved interface / usability / ergonomics
- On-board training / help / facilities installation modes
- Cart mounted or table top configuration with battery operation
- Full compliance with applicable international standards
Ichor’s TriGrid Delivery System for early phase clinical studies was designed for flexibility in administration conditions.
Electroporation (EP) utilizes the application of electrical fields in a target tissue to significantly increase intracellular nucleic acid uptake in the local area, resulting in enhanced gene expression compared to conventional methods of administration.
- Enhanced delivery of nucleic acid drug candidates
- Ease of use for clinical delivery of nucleic acid drugs
- Integrated and automated patented design
- Devices adapted for every phase of development from rodents to humans
Ichor is developing strategic products by incorporating the TriGrid for delivery of nucleic acid candidates into two broad categories:
- Alternative to traditional vaccine approaches
- Prevention of Infectious Diseases
- Immunotherapy / novel vaccine indications
- Oncology
- Chronic viral infection
- Autoimmune disease, allergy
- Alternative to systemic delivery of recombinants
- Approved and/or novel agents
- Low cost, sustained passive immunity (mAb)
- Locoregional protein expression
- Growth factors for revascularization / wound healing
- Immunomodulators